Novamind

Novamind is a neurotechnology company operating at the intersection of psychedelic medicine and psychiatric care, headquartered in Salt Lake City, Utah. The company runs a network of Cedar Psychiatry and Novamind clinics across the United States and Canada, delivering ketamine-assisted therapy as a core clinical offering. Their model integrates evidence-based psychedelic treatments directly into broader psychiatric care frameworks, positioning the clinical environment itself as a therapeutic tool. By combining supervised ketamine infusion protocols with ongoing mental health support, Novamind aims to address treatment-resistant conditions such as depression, anxiety, and PTSD in a structured, medically supervised setting.

Novamind is publicly traded on the TSX Venture Exchange under the ticker NM, reflecting its early but established foothold in the emerging psychedelic medicine market. The company has built one of the more expansive clinical networks in North America dedicated to psychedelic-assisted therapies, giving it both operational scale and a growing base of real-world patient data. In addition to clinical services, Novamind conducts psychedelic clinical research, allowing the company to contribute to the scientific evidence base while identifying new treatment protocols. These parallel tracks of clinical delivery and active research position Novamind to iterate quickly as regulatory frameworks around psychedelic medicine continue to evolve.

Novamind represents an important development in the neurotech industry because it demonstrates a scalable, commercially operational model for psychedelic-assisted mental health treatment. At a time when the global mental health crisis demands novel therapeutic approaches, companies like Novamind serve as proof of concept that psychedelic medicine can be delivered responsibly within regulated clinical infrastructure. Their dual focus on patient care and clinical research accelerates the translation of emerging neuroscience into accessible treatments. As regulatory agencies in both the United States and Canada move closer to broader approval of psychedelic therapies, Novamind's established network and data assets place it in a strong position to lead the next phase of mental health innovation.